Interrater agreement of two scales on the severity of anticoagulant-related major bleeding in patients with venous thromboembolism
- 1 June 2022
- journal article
- letter
- Published by Elsevier in Thrombosis Research
- Vol. 216, 11-13
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Apixaban to Prevent Venous Thromboembolism in Patients with CancerNew England Journal of Medicine, 2019
- Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer StudyThrombosis and Haemostasis, 2018
- Edoxaban for the Treatment of Cancer-Associated Venous ThromboembolismNew England Journal of Medicine, 2018
- Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonistsThrombosis and Haemostasis, 2017
- Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonistsJournal of Thrombosis and Haemostasis, 2015
- Edoxaban versus Warfarin for the Treatment of Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2013
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- The Measurement of Observer Agreement for Categorical DataBiometrics, 1977